|
|
|
Stem Cell Related Patent Number US5843398
| Title: | Radioimmunotherapy of lymphoma using anti-CD20 antibodies | | Inventors: | Kaminski, Mark S.; Ann Arbor, MI, USA
Butchko, Gregory M.; Miami Lakes, FL, USA
Glenn, Stephan D.; Davis, FL, USA
Wahl, Richard L.; Ann Arbor, MI, USA | | Summary: | Described herein is an immunotherapeutic method of treating B-cell lymphoma. The invention relates to the administration of a B cell-specific antibody which binds to CD20 antigens on lymphoma cells, in amounts determined by prior clearance rate studies. Further described are methods by which the patient receives both unlabeled antibodies and antibodies labeled with a radioisotope. Claims of the invention include advantages in tumor response which can be obtained in a radiometric dosage range that does not require hematopoietic stem cell replacement as an adjunct therapy. | | Abstract: | Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US5843398 | | Application Number: | US1996000639882 | | Date Filed: | 26/04/1996 | | Date Published: | 01/12/1998 | | Assignee: | Coulter Pharmaceutical, Inc., Palo Alto, CA, USA
Regents of the University of Michigan, Ann Arbor, MI, USA |
|
|
